A point in time during April next year as a catalyst is an interesting proposition (it appears like you don't know what the word means).
IMO, if you wait for April next year for an entry, there is significant risk that you will be entering at a MUCH MUCH higher price.
So many potential positive events and announcements could occur before that time. One obvious event would be the scheduled release of the DFS occurring within just over the next 3 months (as shown in above attached). Or as i also mentioned above, there could be a takeover offer, or we could receive news of an Offtake Agreement, or a new major player could start buying on-market. These are just a few examples. So many other potential catalysts could occur.
IMO CVV is currently significantly undervalued.
The CVV price has already formed the beginning of a price trend reversal. IMO its possible that we may not see these currently low entry prices again.
- Forums
- ASX - By Stock
- Caravel Copper Project - Bankable Feasibility Study
A point in time during April next year as a catalyst is an...
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CVV (ASX) to my watchlist
|
|||||
Last
18.0¢ |
Change
-0.010(5.26%) |
Mkt cap ! $94.37M |
Open | High | Low | Value | Volume |
19.0¢ | 19.0¢ | 18.0¢ | $41.43K | 221.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 142428 | 18.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.5¢ | 100000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 142428 | 0.180 |
2 | 22500 | 0.175 |
4 | 153832 | 0.170 |
4 | 64730 | 0.165 |
3 | 59200 | 0.160 |
Price($) | Vol. | No. |
---|---|---|
0.195 | 100000 | 1 |
0.200 | 77755 | 4 |
0.205 | 141574 | 1 |
0.210 | 72500 | 2 |
0.220 | 162500 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
CVV (ASX) Chart |